Semaglutide Concurrently Improves Vascular and Liver Indices in Patients With Type 2 Diabetes and Fatty Liver Disease
2024

Semaglutide Improves Vascular and Liver Health in Type 2 Diabetes

Sample size: 75 publication Evidence: moderate

Author Information

Author(s): Ishaq Muhammad Umer, Fatima Noor, Sharif Rida, Awais Warda

Primary Institution: Nishtar Medical College, Nishtar Medical University

Hypothesis

Does semaglutide improve vascular and liver indices in patients with type 2 diabetes and fatty liver disease?

Conclusion

Semaglutide shows benefits in improving both vascular and liver health in patients with type 2 diabetes.

Supporting Evidence

  • Semaglutide improved controlled attenuation parameter and FIB-4 scores.
  • Similar studies have shown semaglutide's benefits on liver health.
  • GLP-1R agonists have hepatoprotective effects and improve liver function.

Takeaway

Semaglutide helps people with diabetes feel better by making their blood vessels and liver healthier.

Methodology

The study involved a 12-month follow-up with a treatment group receiving semaglutide and a control group receiving a different treatment.

Potential Biases

The treatment group was larger than the control group, which could lead to biased results.

Limitations

The small sample size and lack of true placebo may have limited the study's statistical power.

Participant Demographics

Patients with type 2 diabetes and fatty liver disease.

Digital Object Identifier (DOI)

10.1210/jendso/bvae217

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication